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Abstract
Objective
To evaluate the role of genetic variation at the DMPK locus on symptomatic diversity in 250
adult, ambulant patients with myotonic dystrophy type 1 (DM1) recruited to the Observational
Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life—Standards,
a Target Identification Collaboration (OPTIMISTIC) clinical trial.
Methods
We used small pool PCR to correct age at sampling biases and estimate the progenitor allele
CTG repeat length and somatic mutational dynamics, and AciI digests and repeat primed PCR
to test for the presence of variant repeats.
Results
We confirmed disease severity is driven by progenitor allele length, is further modified by age,
and, in some cases, sex, and that patients in whom the CTG repeat expands more rapidly in the
soma develop symptoms earlier than predicted. We revealed a key role for variant repeats in
reducing disease severity and quantified their role in delaying age at onset by approximately
13.2 years (95% confidence interval 5.7–20.7, 2-tailed t test t = −3.7, p = 0.0019).
Conclusions
Careful characterization of the DMPK CTG repeat to define progenitor allele length and
presence of variant repeats has increased utility in understanding clinical variability in a trial
cohort and provides a genetic route for defining disease-specific outcome measures, and the
basis of treatment response and stratification in DM1 trials.
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Myotonic dystrophy type 1 (DM1) is a highly variable
autosomal dominant inherited disorder affecting individu-
als of both sexes and all ages.1 DM1 is caused by the ex-
pansion of a CTG repeat in the DMPK gene that varies in
length from under 40 repeats in the general population to
more than 1,000 repeats in some patients.2–7 Longer CTG
tracts are associated with more severe disease and earlier
age at onset.8–11 However, genotype to phenotype rela-
tionships determined using the traditional diagnostic test
have low predictive value and the International Myotonic
Dystrophy Consortium recommends that families are not
offered predictive phenotypic information based on the size
of the CTG repeat.12
Expanded disease-causing alleles are highly unstable and
usually increase in length during intergenerational
transmission,8,13–15 explaining the decrease in age at onset
of 20–30 years per generation typically observed in DM1
families.16 The expanded CTG is also highly unstable in the
soma in a process that is expansion-biased, age-dependent,
and tissue-specific.17–24 Thus, the average length of the
CTG repeat measured using the traditional diagnostic
depends on the age at which the sample was taken. Pre-
viously, we demonstrated that a sensitive small pool PCR
(SP-PCR) analysis of blood DNA could be used to estimate
the progenitor allele length (ePAL), i.e., the length of the
CTG repeat transmitted to the individual by the affected
parent.18 In addition, we demonstrated that ePAL could
reduce the confounding effects of age at sampling inherent
in the traditional test and we could dramatically improve the
ability to predict age at onset in DM1.25,26
Observational Prolonged Trial in Myotonic Dystrophy Type
1 to Improve Quality of Life—Standards, a Target Identifi-
cation Collaboration (OPTIMISTIC) was a large in-
ternational, multicenter, model-based randomized trial
designed to compare the utility of tailored cognitive be-
havioral therapy (CBT) with an optional graded exercise
plan against standard care.27,28 In order to provide additional
insight into the genetic basis of variability in DM1 and as
a route toward genetic stratification in clinical trials, we
sought to estimate the progenitor allele length and define the
repeat dynamics of the DM1 CTG repeat in the blood DNA
of participants recruited to OPTIMISTIC.
Methods
Standard protocol approvals, registrations,
and patient consents
Full details of the OPTIMISTIC protocol, including power
calculations for sample size, have been reported previously
(Clinicaltrials.gov, NCT02118779).27 All participants were
recruited with informed consent. The protocol was approved
by the National Research Ethics Service Committee North
East—Sunderland (UK), the Comite de Protection des Per-
sonnes ile de France V (France), the Ethikkommission bei der
LMUMu¨nchen (Germany), and the Concernstaf Kwaliteit en
Veiligheid Commissie Mensgebonden Onderzoek Regio
Arnhem-Nijmegen (Netherlands).
Phenotypic data
Ambulant adult patients (>18 years of age) with genetically
proven DM1 capable of providing informed consent with
severe fatigue (Checklist Individual Strength–Fatigue [CIS-
Fatigue] score ≥35) were recruited between April 2014 and
May 2015 through 4 clinical centers: Nijmegen, the Nether-
lands; Paris, France; Munich, Germany; and Newcastle,
United Kingdom (n = 255 [46.3% female] [118/255]).27,28
Exclusion criteria included neurologic or orthopedic comor-
bidity possibly influencing the intervention or outcomes; use
of psychotropic drugs (except modafinil, Ritalin, and anti-
depressants, where the dosing regimen was stable for at least
12 months prior to screening); severe depression; participa-
tion in another interventional clinical trial; or inability to
complete study questionnaires. Age at onset of DM1 symp-
toms was obtained during the trial recruitment screening visit
in answer to the question “At what age did the first medical
problems occur that may be related to your myotonic dys-
trophy?” With the exception of patients recruited through
Munich, age at sampling was calculated based on known date
of birth and the date of visit 2, at which the blood sample was
provided. As a local regulatory requirement, date of birth was
not recorded for participants recruited in Munich, therefore
the age at sampling used was self-reported by participants at
visit 2. Additional baseline (visit 2) clinical measures were
obtained as described in the OPTIMISTIC protocol and
reported previously.27,28 The majority of participants (n =
225) were not known to be related. Eight parent–offspring
pairs, 4 sibling pairs, and 3 trios of 2 siblings and 1 offspring
were also recruited.
Glossary
6-MWT = 6-Minute Walk Test; ASBQ = Adult Social Behavior Questionnaire; BDI-fs = Beck Depression Inventory—fast
screen; CBT = cognitive behavioral therapy; CI = confidence interval; CIS-fatigue = Checklist Individual Strength Fatigue
score;DM1 = myotonic dystrophy type 1; ePAL = estimated progenitor allele length; FDSS = Fatigue and Daytime Sleepiness
Scale;MIRS =Muscle Impairment Rating Scale;OPTIMISTIC =Observational Prolonged Trial in Myotonic Dystrophy Type
1 to Improve Quality of Life—Standards, a Target Identification Collaboration; RP-PCR = repeat-primed PCR; SP-PCR =
small pool PCR; SSL = van Sonderen Social Support List; SSL-D = van Sonderen Social Support List—Discrepancies; SSL-I =
van Sonderen Social Support List—Interactions; SSL-N = van Sonderen Social Support List—Negative Interactions; TMT =
Trail-Making Test.
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DNA samples
A 10-mL venous blood sample was taken from OPTIMISTIC
participants at baseline (time point V2). Blood was collected
into EDTA tubes and stored locally at −80°C. Frozen blood
was shipped on dry ice to the Newcastle Biobank for Research
of Neuromuscular Disorders,29 where DNA was isolated and
shipped to the University of Glasgow. Baseline DNA samples
were available from 250 out of 255 OPTIMISTIC partic-
ipants. Historical DNA samples from OPTIMISTIC partic-
ipants collected during routine molecular diagnosis (from 6
months to 21 years previously) were available for 71 partic-
ipants and obtained from local diagnostic laboratories via the
Newcastle Biobank. Historical DNA samples were not avail-
able for the 5 participants without baseline DNA samples.
SP-PCR and AciI digestion
SP-PCR was carried out using flanking primers DM-C and
DM-DR as previously described18,30 using Custom PCR
Master Mix (Thermo Fisher Scientific [Waltham, MA] #SM-
0005) supplemented with 69 mM 2-mercaptoethanol. Taq
polymerase (Sigma-Aldrich UK, Gillingham) was used at 1
unit per 10 μL. Where required, reactions were supple-
mented with 10% DMSO and the annealing temperature
reduced to 63.5°C. PCR products were digested with AciI
(New England Biolabs UK, Hitchin) in accordance with the
manufacturer’s instructions. DMSO was removed prior to
AciI digestion using the QIAquick (Qiagen, Venlo, the
Netherlands) PCR purification kit. DNA fragments were
resolved by agarose gel electrophoresis and Southern blot
hybridized as described.18,30 Autoradiographic images were
scanned and ePAL and modal allele lengths were estimated
from the lower boundary18 and the densest part of the ex-
panded allele distribution respectively by comparison
against the molecular weight ladder, using CLIQS 1D gel
analysis software (TotalLab UK, Newcastle upon Tyne).
Repeat-primed PCR (RP-PCR)
RP-PCR was performed at the 59-end of the repeat tract
using 1 μM DM-A, 0.1 μM TAG-CAG5, and 1 μM TAG
primer and at the 39-end of the repeat tract using 1 μMDM-
DR, 0.1 μM TAG-CTG5, and 1 μM TAG primer, as de-
scribed previously.31
Statistical analysis
Statistical analyses were undertaken in R (version 3.4.3)32
using RStudio (version 1.0.153).33 There were no repeated
measures and all individuals are represented once in each
statistical analysis. All statistical analyses were 2-sided. Log
transformations of the age at onset, degree of somatic in-
stability, and Stroop interference score were used to better
approximate a normal distribution andminimize the influence
of extreme values. Participants with missing data were ex-
cluded from relevant analyses. Multiple linear regressions
were performed using the lm function from the R Stats
package. In all regression analyses, we report the adjusted r2,
the p value for the overall model, and the coefficient (β) and p
value for each measure. Model selection was based on the
Akaike information criterion for each model using a back-
wards stepwise selection procedure implemented using the
step function in R.34 Confidence intervals (CI) (95%) for
point estimates were calculated where appropriate.
Data availability
The de-identified participant genetic data presented here are
available online (datadryad.org/review?doi=doi:10.5061/
dryad.t063q70). Requests to access the de-identified partici-
pant data from the main OPTMISTIC trial should be
addressed to the trial chief investigator Dr. Baziel van Engelen
(baziel.vanengelen@radboudumc.nl).
Results
Estimation of progenitor and modal allele CTG
repeat lengths in the OPTIMISTIC cohort
In order to investigate genetic variation in the OPTIMISTIC
cohort, we used SP-PCR18 to determine the ePAL, modal
allele length at recruitment, and where available (71 partic-
ipants), modal allele length at molecular diagnosis for the
expanded CTG repeatDMPK allele (figure 1A). An expanded
DMPK CTG repeat allele was readily detected in 241 out of
250 participants using our standard SP-PCR procedure. In an
additional 7 participants, an expanded allele was only detected
after the addition of 10% DMSO to the PCR, consistent with
the presence of GC-rich variant repeats.31 In one of these
individuals, even in the presence of DMSO, only a small
number of expanded alleles was successfully amplified relative
to the non-disease-associated allele and it was not possible to
define the ePAL or modal allele length. In 2 remaining indi-
viduals, we could not successfully amplify an expanded allele,
although in both cases it was possible to amplify a single
nonexpanded allele, consistent with the presence of a non-
amplifiable expanded allele containing a large number of GC-
rich variant repeats (see below for additional analyses). In the
cases where we were able to obtain a historical DNA sample,
the modal allele length had nearly always noticeably increased
in size between the time of diagnosis and recruitment to the
trial (figure 1A). As expected, it was easier to estimate ePAL
from the diagnostic DNA sample obtained at an earlier age,
confirming the value of these historical DNA samples.
Identificationof variant repeatswithin theCTG
arrays of the OPTIMISTIC cohort
Although the majority of patients with DM1 likely inherit
a pure CTG repeat expansion at the DMPK locus, it is known
that a subset of patients contains variant repeat interruptions
within the disease allele.31,35 Such variant repeats, most
commonly CCG and CGG, have been shown to reduce both
germline and somatic instability31 and appear to be associated
with less severe symptoms.31,35–37 Thus, we used SP-PCR to
amplify the CTG repeat tract and test for the presence of
variant repeats by post-PCR digestion with AciI (figure 1B).
AciI recognizes the sequence CCGC and cleaves both CCG
and CGG variant repeats.31 Using this approach, we identified
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variant repeats in 19 out of 248 expanded alleles (7.7%). This
included all the samples that required the addition of DMSO
to facilitate PCR amplification. For the 2 samples for which we
could not amplify the expanded allele, we used RP-PCR31,38,39
to confirm the presence of an expanded allele (figure 1C). The
presence of gaps within the repeat ladder of these 2 partic-
ipants is consistent with the existence of variant repeats within
the expanded allele. Thus, overall, the total frequency of
participants identified with variant repeats in the expanded
allele was 8.4% (21/250 [13/21 female], 95% CI
5.4%–12.7%). This included 1 pair of siblings, in both of
whom we detected variant repeats. Interestingly, we also
detected variant repeats in the daughter of a male transmitting
parent in whom we did not detect variant repeats, consistent
with de novo gain of variant repeats (figure 1B). Similarly, we
also detected variant repeats in only 1 of a pair of siblings,
consistent with either a de novo gain or loss of variant repeats
(figure 1B). Although the proportion of participants with
variant repeats appeared to differ between centers (Munich 5/
65 [7.7%, 95% CI 2.8%–17.8%], Newcastle 4/52 [7.7%, 95%
CI 2.5%–19.4%], Nijmegen 9/66 [13.6%, 95% CI
6.8%–24.8%], Paris 3/67 [4.5%, 95% CI 1.2%–13.4%]), these
differences were not statistically significant (Fisher exact test,
p = 0.32). In one participant, we detected variant repeats in
a 34-triplet large non-disease-associated allele (figure 1B).
Age at onset correlations in the
OPTIMISTIC cohort
Self-reported age at onset of symptoms was available for
229 participants and we used linear regression modeling to
Figure 1 Estimation of progenitor and modal CTG repeat length and detection of AciI-sensitive variant repeats
(A) Shown are representative small pool
PCR (SP-PCR) analyses of repeat length
variation at the DMPK CTG repeat in
blood DNA from 5 individuals. For each
participant, the analysis of 2 DNA sam-
ples is shown: historical sample taken at
time of initial diagnosis (H) and at base-
line (V2). The age at sampling for each
sample is indicated in years. The ap-
proximate positions of the molecular
weight standards converted into the
number of CTG triplet repeats are shown
on the left. The position of the estimated
progenitor allele length for each in-
dividual is indicated with the lower
dashed white line. The modal allele
length at each time point is indicated by
the upper dashed white line. For each
sample, 4 replicate PCRswere performed
with ;180–300 pg DNA. (B) Shown are
representative SP-PCR and AciI diges-
tions of the DMPK CTG repeat in blood
DNA from 7 individuals. For each partic-
ipant, 3 replicate PCRs were performed
with ;500 pg DNA, digested (+) or un-
digested (−) with AciI, resolved by aga-
rose gel electrophoresis and Southern
blot hybridized with a repeat unit probe.
The approximate positions of the mo-
lecular weight standard converted into
the number of CTG triplet repeats of
undigested products is shown on the left.
For each participant the presence (blue)
or absence (red) of AciI-sensitive variant
repeats within the expanded allele is in-
dicated by filled pedigree symbols. Note
OP177 contains AciI-sensitive variant
repeats within the non-disease-associ-
ated allele as indicated by the blue tri-
angle. (C) Detection of expanded alleles
using repeat-primed PCR (RP-PCR).
Shown are 59- and 39-RP-PCR assays for 2
participants (OP251 and OP121) in which
we were not able to amplify the ex-
panded allele using flanking primers. For
both participants, a ladder of products
extending beyond 50 repeats was ob-
served using RP-PCR, confirming the
presence of a disease-causing expan-
sion. Notably, the ladders were discon-
tinuous, consistent with the presence of
variant repeat blocking amplification
from the (CAG)5 or (CTG)5 repeat primer
at some positions within the array. The
approximate positions of the molecular
weight standard converted into the
number of triplet repeats are shown.
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Figure 2 Age at onset and somatic instability correlations
(A) Age at onset is highly correlated with estimated progenitor allele length (ePAL). The scatterplots show the relationship between ePAL and age at onset. The
relevant line of best fit under a logarithmic model for female individuals (circles, orange line), male individuals (squares, lavender line), and sex-averaged for
all individuals (black line,model 1a) (table 1) are shown. Individualswith (blue) andwithout (red) AciI-sensitive variant repeats are also depicted, alongwith the
logarithmic regression line for AciI-sensitive variant repeat carriers (blue line). (B) Effect of variant repeats on age at onset. Shown are boxplots for the
difference in observed age at onset minus predicted age at onset for Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of
Life—Standards, a Target Identification Collaboration (OPTIMISTIC) participants with (yes, blue) and without (no, red) AciI-sensitive variant repeats in their
expanded DMPK allele. Predicted age at onset was derived usingmodel 1a (Ageo = 80.3 + [−23.4 × log(ePAL)]) (table 1). Themean difference in age at onset for
participants carrying AciI-sensitive variant repeats was 13.2 years (95% confidence interval [CI] 5.7 to 20.7, 2-tailed t test t = −3.7, p = 0.0019). The bottom and
top of the box are the lower and upper quartiles, respectively. The band near themiddle of the box is themedian and the notches approximate to the 95% CI
for themedians. Thewhiskers represent the full range of observations bounded by an upper limit equal to the upper quartile plus 1.5× the interquartile range,
and a lower limit equal to the lower quartileminus 1.5× the interquartile range. Any points outside these bounds are displayed individually as small circles. (C)
Modal allele length, ePAL, and presence of AciI variant repeats. The scatterplots show the relationship between ePAL and modal allele length at the V2 time
point. Individuals with (blue) and without (red) AciI-sensitive variant repeats are indicated. (D) Sampling bias in the OPTIMISTIC cohort. The scatterplots show
the relationship between ePAL and age at onset for the OPTIMISTIC cohort (open diamonds, black line) and a family-based DM1 population characterized by
Morales et al.25 (green triangles and line). The relevant line of best fit under a logarithmic model (model 1a, table 1) is shown for each population (for the
OPTIMISTIC cohort n = 222, r2 = 0.178, p = 3.1 × 10−11 and forMorales et al., n = 137, r2 = 0.640, p < 2.2 × 10−16). Note that theMorales et al. cohort hasmore very
mildly affected participants with small expansions, and more severely affected patients with large expansions. (E) ePAL is more informative than the
diagnostic measure in predicting age at onset. The scatterplots show the relationship between age at onset and ePAL (ePAL, open diamonds and black line)
and the diagnostic allele length (diagnostic CTG,maroon diamonds and line) for theOPTIMISTIC cohort. The relevant line of best fit under a logarithmicmodel
(model 1a, table 1) is shown for each CTG measure (for ePAL n = 222, r2 = 0.178, p = 3.1 × 10−11 and for diagnostic CTG n = 105, r2 = 0.123, p = 0.00014).
Neurology.org/N Neurology | Volume 93, Number 10 | September 3, 2019 e999
investigate genotype–phenotype relationships. As expected,25,26,40
ePAL was a major modifier of age at onset (figure 2A and table 1,
model 1a, r2 = 0.178, p = 3.1 × 10−11). The presence of variant
repeats was also highly significantly (p = 2.2 × 10−5) associated
with a later age at onset (figure 2A and table 1, model 1b, r2 =
0.240, p= 3.4 × 10−14). In order to better quantify these effects, we
calculated the age at onset predicted by ePAL alone (i.e., model
1a) and compared this to the observed age at onset. The mean
difference in age at onset between individuals with and without
variant repeatswas 13.2 years (95%CI 5.7 to 20.7, 2-tailed t test t=
−3.7, p = 0.0019, figure 2B). Recently, it has been reported that
there are substantial sex-dependent differences in the relative in-
cidence and severity of some aspects of DM1.41 Similarly, we
recently reported some evidence for sex-dependent genotype–
phenotype correlations in age at onset, although these appeared to
be driven largely by an excess of mildly affected transmitting
grandfathers.40 Here, sex was revealed as having a marginally
significant effect (p = 0.015) on age at onset (table 1, model 1c,
r2 = 0.257, p = 1.2 × 10−14).
Determinants of somatic instability in the
OPTIMISTIC cohort
We defined the degree of somatic instability as the difference
between ePAL and the modal allele at recruitment (time point
V2). As expected,25,40 the major determinants of the degree of
somatic instability were ePAL (figure 2C), age at sampling,
and an interaction between them (table 2, model 2a, r2 =
0.560, p < 2.2 × 10−16). Previously, we also demonstrated in
one family that the presence of variant repeats reduced the
degree of somatic instability.31 Likewise, here the presence or
absence of variant repeats (figure 2C) was revealed as a highly
significant (p = 4.9 × 10−8) additional measure in the re-
gressionmodel (table 2, model 2b, r2 = 0.610, p < 2.2 × 10−16).
In contrast, sex of the participant (p = 0.48) was found not to
Table 1 Age at onset regression models
Model Adjusted r2 p Value Measure Coefficient
Standard
error t Statistic p Value
1a Ageo = β0 + β1Log(ePAL), n = 222 0.178 3.1 × 10
−11 Intercept, β0 80.3 7.9 10.2 <2 × 10
−16
Log(ePAL), β1 −23.4 3.3 −7.0 3.1 × 10
−11
1b Ageo = β0 + β1Log(ePAL) +
β2Variant repeats, n = 222
0.240 3.4 × 10−14 Intercept, β0 86.6 7.7 11.2 <2 × 10
−16
Log(ePAL), β1 −26.5 3.3 −8.0 5.5 × 10
−14
Variant repeats,β2 13.8 3.2 4.3 2.2 × 10
−5
1c Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex, n = 222
0.257 1.3 × 10−14 Intercept, β0 85.6 7.7 11.2 <2 × 10
−16
Log(ePAL), β1 −27.0 3.3 −8.3 1.4 × 10
−14
Variant repeats,β2 14.6 3.2 4.6 7.0 × 10
−6
Sex, β3 3.8 1.6 2.4 0.015
1d Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex +
β4Standardised residuals (SI,
model 2b), n = 222
0.260 2.9 × 10−14 Intercept, β0 85.7 7.6 11.2 <2 × 10
−16
Log(ePAL), β1 −27.0 3.3 −8.3 1.2 × 10
−14
Variant repeats,β2 14.5 3.2 4.6 8.2 × 10
−6
Sex, β3 3.8 1.6 2.4 0.017
Standardized
residuals (SI), β4
−1.0 0.8 −1.3 0.186
1e Ageo = β0 + β1Log(ePAL) +
β2Variant repeats + β3Sex +
β4Standardised residuals (SI,
model 2b) + β4Standardised
residuals (SI, model 2b) ×
Log(ePAL), n = 222
0.304 <2.2 × 10−16 Intercept, β0 104.0 8.8 11.8 <2 × 10
−16
Log(ePAL), β1 −34.8 3.8 −9.2 <2 × 10
−16
Variant repeats,β2 16.6 3.1 5.3 2.7 × 10
−7
Sex, β3 3.6 1.5 2.3 0.020
Standardized
residuals (SI), β4
25.0 6.8 3.7 2.9 × 10−4
Standardized
residuals (SI) ×
log(ePAL), β5
−11.3 2.9 −3.9 1.5 × 10−4
Abbreviations: Ageo = age at onset; SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each model, and
the coefficient (β), standard error, t statistic, and statistical significance (p) associated with each measure in the model. The coefficient (β) provides an
indication of the relative weight of the contribution of eachmeasure to themodel and its associated standard error. The t statistic and corresponding p value
provide an indication of the statistical significance that the measure is adding explanatory power to the model.
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improve the regression model (table 2, model 2c, r2 = 0.609,
p < 2.2 × 10−16).
The role of somatic instability on age at onset
in the OPTIMISTIC cohort
As longer inherited allele lengths precipitate an earlier age at onset
in DM1, and as somatic instability is highly biased toward expan-
sions, it seems logical to expect that individual-specific differences
in the rate of expansion should modify age at onset. Indeed, we
previously established evidence for such an effect in amixed cohort
of patients with DM1 from Scotland, the United States, and Costa
Rica,25 and confirmed this effect in a largeCosta Rican cohort.40 In
theOPTIMISTIC cohort, incorporating the standardized residuals
of somatic instability derived from model 2b into the age at onset
model (table 1, model 1d, r2 = 0.260, p = 3.0 × 10−14) improved
the r2 value slightly from model 1c, but the standardized residuals
of somatic instability did not reach statistical significance as
ameasure (p= 0.19).However, when the standardized residuals of
somatic instability were included with an interaction with ePAL,
themodel was improved further (table 1, model 1e, r2 = 0.304, p <
2.2 × 10−16) and both the standardized residuals of somatic in-
stability alone (p = 2.9 × 10−4) and the interaction with ePAL (p =
1.5 × 10−4) were revealed as highly significant measures.
Genetic correlations with progressive
phenotypes in the OPTIMISTIC cohort
As part of the OPTIMISTIC protocol, several DM1 pheno-
types were also quantified at baseline using a variety of direct
and indirect (i.e., questionnaires) assessment tools.27 To in-
vestigate the genotype–phenotype relationships of these
progressive phenotypes, we applied a model selection process
incorporating ePAL, residual variation in somatic instability,
variant repeats, sex and age at baseline, and interactions be-
tween ePAL, residual variation in somatic instability, and age
at baseline (table 3). Highly significant associations with effect
sizes comparable to those observed with age at onset were
revealed for many measures (table 3 and figure 3), including
the Muscle Impairment Rating Scale (MIRS, r2 = 0.32, p = 2.6
× 10−19), the OPTIMISTIC primary outcome, the DM1-
Activ-c score (r2 = 0.23, p = 2.9 × 10−13), and key secondary
outcomes such as the 6-MinuteWalk Test (6-MWT, r2 = 0.31,
p = 2.3 × 10−18), physical activity (accelerometry, mean, r2 =
0.25, p = 3.9 × 10−10, and most active 5-hour, r2 = 0.25, p = 8.9
× 10−12), the Trail-Making Test (TMT-A, r2 = 0.23, p = 2.2 ×
10−14, and TMT-B, r2 = 0.24, p = 4.5 × 10−12), and the Stroop
interference score (r2 = 0.21, p = 2.8 × 10−12). Moderate
associations were observed for the Adult Social Behavior
Questionnaire (ASBQ, r2 = 0.11, p = 1.6 × 10−4), the Apathy
Evaluation Scale–Clinician Version (r2 = 0.10, p = 5.1 × 10−5),
the Fatigue and Daytime Sleepiness Scale (FDSS) (r2 = 0.09,
p = 2.9 × 10−5), the Myotonic Dystrophy Health Index total
score (r2 = 0.09, p = 3.4 × 10−5), and Self-Efficacy–Scale 28 for
Fatigue (r2 = 0.07, p = 2.2 × 10−4). Only weak or statistically
nonsignificant associations were observed for a number of
measures, including for van Sonderen Social Support List
(SSL) (SSL—Discrepancies [SSL-D], SSL—Interactions
Table 2 Regression models of the determinants of the degree of SI
Model Adjusted r2 p Value Measures Coefficient
Standard
error t Statistic p Value
2a Log(SI) = β0 + β1Log(ePAL) +
β2Ages +β3Log(ePAL) × Ages,
n = 247
0.560 <2.2 × 10−16 Intercept, β0 1.72 0.73 2.37 0.019
Log(ePAL), β1 0.20 0.30 0.66 0.509
Ages, β2 −0.05 0.01 −3.73 2.4 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 3.90 1.3 × 10
−4
2b Log(SI) = β0 + β1Log(ePAL) +
β2Ages + β3Log(ePAL) × Ages
+ β4VariantRepeats, n = 247
0.610 <2.2 × 10−16 Intercept, β0 1.50 0.69 2.19 0.029
Log(ePAL), β1 0.29 0.28 1.03 0.304
Ages, β2 −0.05 0.01 −3.94 1.1 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 4.17 4.2 × 10
−5
Variant repeats, β4 −0.39 0.07 −5.63 4.9 × 10
−8
2c Log(SI) = β0 + β1Log(ePAL) +
β2Ages + β3Log(ePAL) × Ages
+ β4VariantRepeats + β5Sex,
n = 247
0.609 <2.2 × 10−16 Intercept, β0 1.49 0.69 2.17 0.031
Log(ePAL), β1 0.30 0.28 1.06 0.292
Ages, β2 −0.05 0.01 −3.92 1.2 × 10
−4
Log(ePAL) × Ages, β3 0.02 0.01 4.16 4.5 × 10
−5
Variant repeats, β4 −0.39 0.07 −5.67 4.1 × 10
−8
Sex, β5 −0.02 0.04 −0.71 0.481
Abbreviation: SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each model, and
the coefficient (β), standard error, t statistic, and statistical significance (p) associated with each measure in the model.
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Table 3 Regression models of the determinants of progressive phenotypes
Dependent variable Direction
Overall model
Parameter
Age Log(ePAL)
n r2 p Value β p Value β p Value
Muscle impairment rating scale L 247 0.32 3 × 10−19 −0.06 0.08 −0.1 0.92
6-min walk test distance (m) H 246 0.31 2 × 10−18 2.89 0.57 −62.7 0.56
Physical activity (most active 5-h) H 198 0.25 9 × 10−12 −1.11 5 × 10−9 −60.0 5 × 10−11
Physical activity (mean) H 198 0.25 4 × 10−10 −0.10 0.87 −16.4 0.23
Trail making test—A L 234 0.24 5 × 10−12 3.14 0.20 97.6 0.06
Trail making test—B L 242 0.23 2 × 10−14 0.82 2 × 10−15 22.4 3 × 10−6
DM1-Activ-c H 246 0.23 3 × 10−13 0.43 0.57 −3.3 0.84
Log (Stroop interference score) L 238 0.21 3 × 10−12 0.02 3 × 10−12 0.7 2 × 10−5
Adult social behavioural questionnaire L 201 0.11 0.0002 0.99 0.17 31.5 0.03
Apathy evaluation scale—clinician score L 241 0.10 5 × 10−5 0.45 0.38 20.0 0.07
Fatigue and daytime sleepiness scale L 242 0.09 3 × 10−5 1.04 0.04 15.6 0.15
Myotonic dystrophy health index L 245 0.09 3 × 10−5 0.43 2 × 10−5 17.7 0.0003
Self-efficacy scale 28 for fatigue H 241 0.07 0.0002 −0.04 0.02 −2.4 0.002
Van Sonderen social support—discrepancies L 196 0.05 0.01 0.22 0.02 9.7 0.04
Illness cognition questionnaire H 237 0.04 0.02 0.17 0.45 3.5 0.47
Van Sonderen social support—interactions H 216 0.04 0.02 −0.20 0.06 −10.7 0.09
Individualised neuromuscular quality of life
questionnaire—subscale quality of life
L 245 0.04 0.03 −3.56 0.07 −63.2 0.13
Checklist individual strength—fatigue subscale L 247 0.03 0.01 0.07 0.04
Sickness impact profile L 156 0.03 0.02 78.6 0.02
McGill pain score L 233 0.03 0.02 15.4 0.03
Jacobsen fatigue catastrophizing scale L 241 0.02 0.03 0.09 0.06 5.4 0.01
Apathy evaluation scale—informant version L 99 0.02 0.32
Beck depression inventory—fast screen L 243 0.01 0.18 0.16 0.36 3.8 0.31
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Table 3 Regression models of the determinants of progressive phenotypes (continued)
Dependent variable Direction
Overall model
Parameter
Age Log(ePAL)
n r2 p Value β p Value β p Value
Illness management questionnaire L 241 0.01 0.28 0.44 0.42 11.1 0.33
Van Sonderen social support—negative interactions L 218 0.00 0.35 1.4 0.22
Physical activity (least active 5-hour) L 198 −0.02 0.82
Caregiver strain index L 98 −0.07 0.98
Dependent variable
Standardized
residuals (SI,
model 2b) Variant repeats Sex (Male) Log(ePAL) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b)
Standardized
residuals (SI,
model 2b) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b) ×
Age
β p Value β p Value β p Value β p Value β p Value β p Value β p Value
Muscle impairment rating scale 0.3 2 × 10−8 −0.8 6 × 10−5 0.04 0.02
6-min walk test distance (m) −25.2 0.0001 115.2 1 × 10−5 51.9 0.0001 −3.24 0.13
Physical activity (most active 5-h) −4.3 0.03 22.2 0.003 9.0 0.02
Physical activity (mean) 33.6 0.12 9.6 0.001 2.2 0.13 −0.14 0.60 −14.5 0.12 −0.64 0.14 0.26 0.17
Trail making test—A −158.8 0.06 −30.2 0.007 −0.45 0.66 71.4 0.05 2.93 0.09 −1.32 0.08
Trail making test—B −8.9 0.04
DM1-Activ-c −1.6 0.10 12.4 0.001 −0.48 0.14
Log (Stroop interference score) −0.5 0.001
Adult social behavioural questionnaire −88.5 0.0004 −5.6 0.07 4.4 0.007 −0.40 0.19 37.0 0.0007 1.88 0.001 −0.80 0.001
Apathy evaluation scale—clinician score −46.8 0.009 −7.0 0.002 −0.15 0.49 22.5 0.004 0.81 0.02 −0.39 0.01
Fatigue and daytime sleepiness scale −6.5 0.01 −3.7 0.005 −0.36 0.09
Myotonic dystrophy health index 1.7 0.10 −6.6 0.11
Self-efficacy scale 28 for fatigue −0.5 0.01 0.8 0.02
Van Sonderen social support—discrepancies −6.1 0.08 3.6 0.08
Illness cognition questionnaire 16.7 0.04 1.4 0.007 −0.08 0.44 −7.5 0.03 −0.33 0.04 0.15 0.04
Van Sonderen social support—interactions 21.9 0.03 6.2 0.15 −5.6 0.01 −9.6 0.03
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Table 3 Regression models of the determinants of progressive phenotypes (continued)
Dependent variable
Standardized
residuals (SI,
model 2b) Variant repeats Sex (Male) Log(ePAL) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b)
Standardized
residuals (SI,
model 2b) × Age
Log(ePAL) ×
Standardized
residuals (SI,
model 2b) ×
Age
β p Value β p Value β p Value β p Value β p Value β p Value β p Value
Individualised neuromuscular quality of life
questionnaire—subscale quality of life
90.1 0.19 1.78 0.04 −42 0.16 −2.26 0.10 1.07 0.08
Checklist individual strength—fatigue subscale −4.0 0.01 0.09 0.006
Sickness impact profile
McGill pain score −6.5 0.06
Jacobsen fatigue catastrophizing scale
Apathy evaluation scale—informant version
Beck depression inventory—fast screen −17.1 0.007 −0.06 0.42 7.6 0.005 0.29 0.02 −0.13 0.02
Illness management questionnaire −25.6 0.17 −0.18 0.44 11.5 0.15 0.64 0.09 −0.29 0.08
Van Sonderen social support—negative
interactions
−3.6 0.10 1.6 0.09
Physical activity (least active 5-hour)
Caregiver strain index
Abbreviation: SI = somatic instability.
The table shows the number of observations (n), adjusted squared coefficient of correlation (adjusted r2), and statistical significance (p) for each overall model for each dependent variable (phenotype), and the coefficient (β)
and statistical significance (p) associated with eachmeasure in themodel and their interactions (×). The direction indicates whether a higher (H) or lower (L) score for the phenotype represents a better (i.e., “healthier”) result for
the individual. Note that the blank cells correspond to independent variables that were rejected by the model selection procedure, as their inclusion did not significantly improve the overall regression model for the given
phenotype.
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[SSL-I], and SSL—Negative Interactions [SSL-N]), CIS-
Fatigue, the McGill Pain Questionnaire, the Sickness Impact
Profile, and the Beck Depression Inventory—fast screen
(BDI-fs), all r2 < 0.05, p > 0.01, and n > 150 (table 3). For all
of the highly associated measures (r2 > 0.15), age, ePAL, and
presence of variant repeats were revealed as important ex-
planatory variables (table 3). The relative degree of somatic
mosaicism was also an important explanatory variable for all
Figure 3 Estimated progenitor allele length (ePAL) and variant repeat correlations with age-dependent phenotypes
The scatterplots show the relationship between ePAL and a number of age-dependent phenotypes. The relevant line of best fit under a logarithmic model
(dependent variable = β0 + β1Log[ePAL]) for female individuals (circles, orange line), male individuals (squares, lavender line), and sex-averaged for all
individuals (black line) are shown. Individuals with (blue) and without (red) AciI-sensitive variant repeats are also depicted, along with the logarithmic
regression line for AciI-sensitive variant repeat carriers (blue line).
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bar the Stroop interference score and TMT-A. Sex was also an
important modifier for the 6-MWT and physical activity
(accelerometry, mean, and most active 5-hour) (table 3).
Discussion
We analyzed the length and dynamics of the disease-causing
CTG repeat expansion in the DMPK gene to reveal the pri-
mary genetic determinants of symptomatic variation in the
OPTIMISTIC cohort. As expected, we were able to establish
ePAL as a major determinant of self-reported age at onset (table
1, model 1a). However, it is notable that the proportion of
variance in age at onset explained by ePAL (r2 = 0.178) was
much lower than observed in previous studies (e.g., r2 = 0.640 in
Morales et al.25). This is attributable to the eligibility constraints
for recruitment to OPTIMISTIC that dictated that participants
must be aged at least 18 years, have severe fatigue (CIS-Fatigue
severity score ≥35), but nonetheless retain the ability to walk
independently, and be able to provide informed consent and be
motivated to undergo CBT. Thus, OPTIMISTIC has fewer
very mildly affected participants with small expansions, and
fewer severely affected patients with very large DM1 expansions
(figure 2D). Selection of moderately affected patients is likely to
be a common feature of many of the early DM1 trials, sug-
gesting that the genetic characteristics and phenotypic rela-
tionships of the OPTIMISTIC cohort will likely be
representative of other DM1 trial cohorts. Although age at onset
is an important aspect of the disease phenotype, it is somewhat
subjective in its assessment as it may depend on patient recall,
patient knowledge and relative cognition, and insight.42 More-
over, age at onset is unlikely in the near term to be an outcome
measure in clinical trials. We have also revealed that ePAL is an
important contributor to multiple age-dependent phenotypes
that were also assessed as part of the OPTIMISTIC protocol,
including key measures of muscle function and activity such as
the MIRS, 6MWT, DM1-Activ-c, and accelerometry data, and
key CNS phenotypes such as the TMT and Stroop test. In
contrast, other phenotypes such as SSL-D/I/N, CIS-Fatigue,
McGill pain, and BDI-fs were not well-explained by genetic
factors. It seems reasonable to assume that in general symp-
toms that are strongly associated with the causative mutation in
DM1 are most directly linked to the underlying disease process
and may be the most responsive to therapeutic interventions
targeting the underlying pathology. It is also possible that some
of the more subjective self-reported measures may also be
compromised by reduced patient insight,42 further confound-
ing genotype to phenotype associations.
For many years it was assumed that expanded alleles at the
DMPK locus comprised pure CTG repeat arrays. However, it
has become apparent that a subset of DM1 expansions con-
tains variant repeats.31,35,37,43,44 Previous estimates for the
frequency of such variants in unselected DM1 cohorts vary
from ;3% to 5%.31,35–37 Here, we determined the overall
frequency of variant repeats as 8.4% of the total cohort (21/
250). In the Nijmegen subcohort, the frequency of variants
was 13.6% (9/66, 95% CI 6.8%–24.8%), while in the Paris
subcohort it was only 4.5% (3/67, 95% CI 1.2%–13.4%).
Although there was 1 pair of siblings from Nijmegen who
shared variant repeats, none of the other participants from
Nijmegen with variant repeat containing expanded alleles
were known to be related to each other. Thus, chance sam-
pling of one or a few large families segregating variant repeat
alleles does not explain the higher frequency of variant repeat
alleles observed in the Nijmegen subcohort. While it is pos-
sible that this may reflect some sort of site-specific recruitment
bias, this difference was not statistically significant and may
simply represent random sampling error. Regardless, the
presence of variant repeats clearly influences disease severity,
with individuals carrying such alleles having an age at onset
delayed by an average of ;13 years relative to that predicted
using the 1a regression model. It is possible that the reduced
disease severity observed inDM1 carriers of repeat alleles led to
their overselection in OPTIMISTIC, conceivably mediated by
a reduced neuropsychological effect of the disease and higher
motivation among this subcohort. In addition to modifying age
at onset, these data also reveal the protective effect of variant
repeats on many of the progressive phenotypes likely to be
outcomes in clinical trials. If variant repeat carriers are over-
recruited, this may reduce sensitivity to correctly evaluate ef-
ficacy of a therapeutic intervention in a clinical trial. These
considerations suggest that testing for the presence of variant
repeats should be included in DM1 trial design.
Recently, it has been demonstrated that the absolute frequency
and severity of different aspects of the complex DM1 phenotype
are differentially expressed in male and female patients.41 Simi-
larly, we have presented preliminary evidence that suggest there
may also be subtle repeat-length-independent sex effects on age
at onset.40 Here, we also observed a marginally significant sex
effect (p = 0.015) when including sex as a measure in the age at
onset model (table 1, model 1c). However, the direction of this
effect was the opposite to that previously observed. These
observations suggest sex has only a subtle effect on overall age at
onset. Nonetheless, sex was revealed as an important cofactor for
some phenotypes such as the 6MWT, the ASBQ, and the FDSS
(table 3) and should be considered as an important factor in
clinical trials.
We recently demonstrated that residual variation in somatic
instability not accounted for by age at sampling and ePAL was
inversely correlated with residual variation in age at onset not
accounted for by ePAL, i.e., patients in whom the repeat
expands more rapidly in the soma have earlier ages at onset
than expected.25,40 Here, we have used SP-PCR to calculate
the modal length change during the lifetime of the patient as
a measure of somatic instability and shown variation in this
measure is explained by the expected measures, i.e., ePAL, age
at sampling, and a strong interaction between them (table 2,
model 2a). In addition, we have confirmed that somatic in-
stability is reduced by the presence of variant repeats. We have
also provided additional evidence that somatic mutational
dynamics directly modify disease severity, with residual
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variation in somatic instability accounting for approximately
4.7% of the total variation in age at onset and detectably
contributing to many age-dependent phenotypes and con-
firming somatic expansion as an important therapeutic target.
Traditionally, DM1 is diagnosed using Southern blot hybrid-
ization of restriction digested genomic DNA. The low pre-
dictive value of this measure and additional complications
mediated by a failure to fully consider the effects of age-
dependent somatic expansion on interpreting intergenerational
length changes prompted the International Myotonic Dystro-
phy Consortium to recommend that families not be offered
predictive phenotypic information based on the number of
CTG repeats.12 While this recommendation is not universally
observed, this suggestion, coupled with the technical challenges
of Southern blot hybridizations and the availability of a simple
yes/no RP-PCR test,39 has led to a situation where many di-
agnostic laboratories do not even attempt to measure the
number of CTG repeats. For example, within the OPTIMIS-
TIC cohort, a diagnostic CTG repeat length was available for
only 121 out of 255 participants. As expected, the predictive
value of this measure was relatively low, the diagnostic CTG
length measure accounting for only 12% of the variation in age
at onset (figure 2E, n = 103, r2 = 0.123, p = 0.00014). This
contrasts sharply with the;30% of variation accounted for by
estimating progenitor allele length, quantifying somatic mosa-
icism, and determining the presence or absence of variant
repeats (table 1, model 1e). These data suggest that it may be
time to revisit the recommended diagnostic criteria for DM1
and the potential value of reporting more informative prog-
nostic information to families by estimating progenitor allele
length and testing for the presence of variant repeats.
We have defined the genetic characteristics of the DMPK
expansion in the cohort of patients with DM1 recruited to the
OPTIMISTIC clinical trial. These baseline data have already
yielded important insights into genotype to phenotype rela-
tionships in DM1 and should provide a route to determining
the possible effect of genotype on intervention response and
a basis for genetic stratification of DM1 trial participants.
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Disputes & Debates: Editors’ Choice
Steven Galetta, MD, FAAN, Section Editor
Reader response: Menarche, pregnancies, and breastfeeding do not
modify long-term prognosis in multiple sclerosis
Vilija G. Jokubaitis (Melbourne) and Ruth Dobson (London)
Neurology® 2020;94:455–456. doi:10.1212/WNL.0000000000009063
We read with interest the article by Zuluaga et al.,1 which used the uniquely valuable Barcelona
CIS (clinically isolated syndrome) cohort.2 However, evolving multiple sclerosis (MS) di-
agnostic and treatment landscapes must be taken into account when using this cohort to inform
current practice.
Of those included in the analysis,1 47%did not have a second clinical attack, 39%did notmeet the
McDonald 2010 criteria, and 32% did not meet the Barkhof criteria for the diagnosis ofMS. This
Editors’ note: Menarche, pregnancies, and breastfeeding do not
modify long-term prognosis in multiple sclerosis
In the article, “Menarche, pregnancies, and breastfeeding do not modify long-term prog-
nosis in multiple sclerosis,” Zuluaga et al. reported that age at menarche, pregnancy before
or after the diagnosis of clinically isolated syndrome (CIS), and breastfeeding did not
substantially modify the risk of progressing to clinically definite multiple sclerosis (CDMS)
or disability accrual per the Expanded Disability Status Scale (EDSS) in a cohort of 501
female participants with CIS. In response, Drs. Jokubaitis and Dobson argued that the
patients with CDMS should be examined separately for the EDSS outcomes because
a substantial proportion of the overall cohort did not have a second clinical attack and did
notmeet either theMcDonald 2010 or Barkhof criteria forMS. They seek additional details
regarding the propensity score–matched score analysis because a smaller number of
matched pairs could limit the generalizability of the results. In addition, they noted that the
analyses for the association of pregnancy and breastfeeding on time to EDSS 3.0 were not
adjusted for relapse and that the differences between exclusive breastfeeding and mixed
feeding strategies merit further exploration in prospective studies. They also argue that the
harmful effects of suspending disease-modifying treatments (DMTs) in those with ag-
gressive disease who become pregnant should be considered. Responding to these com-
ments, Drs. Tintore´ et al. noted that they built the model for time to EDSS 3.0 over the
CDMS subcohort, in addition to providing further details of the propensity score–matched
analyses. They reported additional analyses for the adjusted hazard ratio for pregnancy (but
not for breastfeeding) on considering the annualized relapse rate over the first 3 and 5 years
of disease and acknowledged that additional details of breastfeeding were unavailable.
Regarding the problem of suspending DMTs in pregnant patients, they noted that they are
analyzing a subgroup of women treated with natalizumab or fingolimod. As greater
numbers of young women become eligible for DMTs with more inclusive revisions of the
McDonald criteria, neurologists are likely to encounter challenging questions about the
association of pregnancies and breastfeeding with MS disease activity, and the attendant
DMT-related dilemmas, in their practice.
Aravind Ganesh, MD, DPhil, and Steven Galetta, MD
Neurology® 2020;94:455. doi:10.1212/WNL.0000000000009064
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raises questions about cohort baseline heterogeneity because 2 of the primary outcomemeasures
are confirmed Expanded Disability Status Scale (EDSS) 3.0 or 6.0. There is an argument in favor
of examining the clinically definite multiple sclerosis (CDMS) cohort separately to the non-
CDMS cohort.
Regarding the propensity score-matched analyses, we are interested to know the matching
strategy used, how many matched pairs were included in this analysis, the matching ratio, the
median follow-up duration, and censoring strategy. Only 142 respondents had pregnancies after
a CIS1; it is thus possible that fewer than 142 matched pairs were included, limiting the gen-
eralizability of these results.
It appears that the analyses of the impact of pregnancy and breastfeeding on time to EDSS 3.0
were not adjusted for relapse. Relapse, particularly early in the disease phase, and relapse recovery
are among the strongest predictors of future disability accumulation.3,4
Breastfeeding was studied as both a dichotomous variable (breastfeeding vs not) and a time-
dependent event.1 However, exclusive breastfeeding may be protective in a way that mixed
feeding is not.5 A truly prospective design is required to address the subtleties of this question.
The authors concluded that MS prognosis is not significantly affected by pregnancy once all
other variables are considered.1 However, in the current era of highly active disease-modifying
treatment (DMT) use, pregnancy does not occur in isolation. The potentially harmful effects of
suspending DMT in those with aggressive disease must be taken into account when discussing
family planning in MS. We look forward to future studies to help answer the questions that this
study raises, which is of prime importance to women with MS.
1. Zuluaga MI, Otero-Romero S, Rovira A, et al. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple
sclerosis. Neurology 2019;92:e1507–e1516.
2. TintoreM, Rovira A`, Rı´o J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 2015;
138:1863–1874.
3. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol
2013;73:95–103.
4. Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol
2016;80:89–100.
5. Hellwig K, Rockhoff M, Herbstritt S, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA
Neurol 2015;72:1132–1138.
Copyright © 2020 American Academy of Neurology
Author response: Menarche, pregnancies, and breastfeeding do not
modify long-term prognosis in multiple sclerosis
Mar Tintore´ (Barcelona, Spain), Santiago Perez-Hoyos (Barcelona, Spain), and Susana Otero-Romero
(Barcelona, Spain)
Neurology® 2020;94:456–457. doi:10.1212/WNL.0000000000009065
We thank Drs. Jokubaitis and Dobson for the comment on our article.1
We built the model for the time to Expanded Disability Status Scale (EDSS) 3.0 over the
clinically definite multiple sclerosis (CDMS) subcohort. The adjusted hazard ratio (aHR [CI
95%]) associated to pregnancy is aHR = 1.26, CI 95% (0.62, 2.59).
Regarding the propensity score–matched analyses, we decided to perform inverse probability
(IP) weighting to create the new pseudocohort to minimize the association between covariates
and pregnancy status. Thus, no matching was performed, but we assigned IP weights to each of
the patients in the cohort. The probability of being pregnant at any time, given the set of
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covariates, was estimated via a logistic regression adjusted for age at clinically isolated syndrome
(CIS), topography of the CIS, oligoclonal bands (OB), number of T2 baseline lesions, treat-
ment status (as time dependent), number of T2 lesions at first year, and CDMS (as time
dependent).
We totally agree with the issue noted about not adjusting for relapse in the analyses of impact of
pregnancy and breastfeeding on time to EDSS 3.0. Incorporating relapses in the adjusted model
is key to predict disability. The adjusted hazard ratio for pregnancy, considering the annualized
relapse rate over the first 3 years of disease, is aHR = 1.15, CI 95% (0.56, 2.36). When
computing the annualized relapse rate within the first 5 years of disease, we obtain an aHR =
1.45, CI 95% (0.70, 3.02). A further step that we are exploring for this analysis is to include
relapses as a time-varying event with the aim of approaching in a more realistic way the dynamic
nature of the disease. We also agree that future research must focus on more precise modalities
of breastfeeding, such as mixed or exclusive breastfeeding. Unfortunately, this information was
missing in our study.1
In the era of high-efficacy drugs, suspending disease-modifying treatments may be harmful for
patients with aggressive multiple sclerosis. To answer the questions our study raised, we are in
the process of independently analyzing a subgroup of pregnant women treated with natalizu-
mab or fingolimod.
1. Zuluaga MI, Otero-Romero S, Rovira A, et al. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple
sclerosis. Neurology 2019;92:e1507–e1516.
Copyright © 2020 American Academy of Neurology
Editors’ note: Teaching NeuroImages: A rare case of Jacobsen
syndrome with global diffuse hypomyelination of brain
In the article “Teaching NeuroImages: A rare case of Jacobsen syndrome with global diffuse
hypomyelination of brain,” Patel et al. presented MRI fluid-attenuated inversion recovery
(FLAIR) images at 18months and 3 years of age in a boywith Jacobsen syndrome due to an
11q23-11q24 deletion. The images showed improvement in white matter abnormalities,
which were termed hypomyelination by the authors. In response, Wolf et al. argued that
hypomyelination is a permanentmyelin deficit and is associated with a less hyperintense T2
white matter signal than is seen in this patient. They noted that the patient’s deletion
encompasses HEPACAM, a gene for which haploinsufficiency is associated with leuko-
dystrophy that improves with time. They noted that the case is representative of limitations
in extant classifications of leukodystrophies as either hypomyelinating or demyelinating.
Responding to these comments, Patel et al. agreed that HEPACAM loss of function may
account for some of the imaging abnormalities in Jacobsen syndrome but noted that
macrocephaly and cysts (classical findings with HEPACAM mutations) are not typically
seen in this syndrome. They noted that the original neuroradiologist interpretation termed
the findings as global diffuse hypomyelination. This exchange highlights current uncer-
tainties in the terminology surrounding the white matter abnormalities, particularly in the
pediatric population.
Aravind Ganesh, MD, DPhil, and Steven Galetta, MD
Neurology® 2020;94:457. doi:10.1212/WNL.0000000000009066
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Reader response: Teaching NeuroImages: A rare case of Jacobsen
syndrome with global diffuse hypomyelination of brain
Nicole I. Wolf (Amsterdam) and Marjo S. van der Knaap (Amsterdam)
Neurology® 2020;94:458. doi:10.1212/WNL.0000000000009070
With interest we read the report by Patel et al.1 concerning a patient with Jacobsen syndrome
due to an 11q23–11q24 deletion and MRI evidence for leukodystrophy with improvement at
a follow-up, substantiated by FLAIR images. The authors claimed that these abnormalities
represent hypomyelination. Hypomyelination is defined as a significant and permanent myelin
deficit.2 Its MRI appearance is characterized by a diffusely hyperintense T2 white matter (WM)
signal, which is less high than the signal in other leukodystrophies2,3 and certainly less high than
the WM signal in the patient discussed here,1 who has strongly T2-hyperintense WM signal
abnormalities.
The chromosomal deletion encompasses HEPACAM. Heterozygous and biallelic mutations in
this gene cause megalencephalic leukodystrophy with subcortical cysts (MLC), a vacuolating
leukodystrophy with macrocephaly. In dominantHEPACAMmutations, the leukodystrophy
improves over time.4 In Jacobsen syndrome,HEPACAM haploinsufficiency was earlier assumed
to cause leukodystrophy.5
Why did the authors classify their case as hypomyelination? Many neurologists still categorize
leukodystrophies in hypomyelinating and demyelinating disorders.3 Perhaps the MRI im-
provement, not compatible with a demyelinating (progressive) disorder, prompted them to
label this leukodystrophy hypomyelination? This case nicely illustrated that not all leukodys-
trophies are progressive and that there are more leukodystrophy categories beyond hypo-
myelination and demyelination.3
1. Patel H, Kumar A, Raymond G, Mainali G. Teaching NeuroImages: a rare case of Jacobsen syndrome with global diffuse hypo-
myelination of brain. Neurology 2019;92:e1665–e1666.
2. Pouwels PJ, Vanderver A, Bernard G, et al. Hypomyelinating leukodystrophies: translational research progress and prospects. Ann
Neurol 2014;76:5–19.
3. van der KnaapMS, Schiffmann R,Mochel F, Wolf NI. Diagnosis, prognosis and treatment of the leukodystrophies. Lancet Neurol 2019;
18:962–972.
4. van der KnaapMS, Boor I, Este´vez R. Megalencephalic leukoencephalopathy with subcortical cysts: chronic white matter oedema due to
a defect in brain ion and water homoeostasis. Lancet Neurol 2012;11:973–985.
5. Yamamoto T, Shimada S, Shimojima K, et al. Leukoencephalopathy associated with 11q24 deletion involving the gene encoding hepatic
and glial cell adhesion molecule in two patients. Eur J Med Genet 2015;58:492–496.
Copyright © 2020 American Academy of Neurology
Author response: Teaching NeuroImages: A rare case of Jacobsen
syndrome with global diffuse hypomyelination of brain
Himadri Patel (Hershey, PA), Ashutosh Kumar (Hershey, PA), Gerald Raymond (Hershey, PA),
and Gayatra Mainali (Hershey, PA)
Neurology® 2020;94:458–459. doi:10.1212/WNL.0000000000009069
We thank Drs. Wolfe and Van der Knaap for their insightful comment, on our Teaching
NeuroImages study,1 and clarification of their precise definition of hypomyelinating
disorders. We agree that HEPACAM loss of function may account for some of the issue
in imaging in Jacobsen syndrome, but it does not appear to be the entire explanation,
given the lack of macrocephaly or cysts in most patients reported. Regarding the hypo-
myelination classification, this was derived from the original radiology report, interpreted
458 Neurology | Volume 94, Number 10 | March 10, 2020 Neurology.org/N
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by the neuroradiologist, as a global diffuse hypomyelination with mild diffuse brain atrophy.
Further longitudinal studies would certainly be of interest.
1. Patel H, Kumar A, Raymond G, Mainali G. Teaching NeuroImages: a rare case of Jacobsen syndrome with global diffuse hypo-
myelination of brain. Neurology 2019;92:e1665–e1666.
Copyright © 2020 American Academy of Neurology
CORRECTIONS
Clinical and neural responses to cognitive behavioral therapy for
functional tremor
Neurology® 2020;94:459. doi:10.1212/WNL.0000000000008714
In the article “Clinical and neural responses to cognitive behavioral therapy for functional tremor”
by Espay et al.,1 the full author’s name should have appeared throughout as W. Curt LaFrance, Jr.
The authors regret the error.
Reference
1. Espay AJ, Ries S, Maloney T, et al. Clinical and neural responses to cognitive behavioral therapy for functional tremor. Neurology 2019;
93:e1787–e1798.
Clinical risk factors in SUDEP
Anationwide population-based case-control study
Neurology® 2020;94:459. doi:10.1212/WNL.0000000000009154
In the article “Clinical risk factors in SUDEP: A nationwide population-based case-control
study” by Sveinsson et al.,1 the bottom box in figure 1 should read “n = 255” and the fifth box
down on the right should read “Controls.” The editorial staff regret the errors.
Reference
1. Sveinsson O, Andersson T, Mattsson P, Carlsson S, Tomson T. Clinical risk factors in SUDEP: a nationwide population-based case-
control study. Neurology 2020;94:e419–e429.
Genetic determinants of disease severity in the myotonic dystrophy
type 1 OPTIMISTIC cohort
Neurology® 2020;94:459. doi:10.1212/WNL.0000000000008715
In the article “Genetic determinants of disease severity in the myotonic dystrophy type 1
OPTIMISTIC cohort” by Cumming et al.,1 the study funding section should have read “Study
funded by European Union’s Seventh Framework Programme (FP7/2007–2013) under grant
agreement number 305697 (the OPTIMISTIC project), the Wellcome Centre for Mito-
chondrial Research (ref 203105/Z/16/Z)), and donations to the DGM group from the
Myotonic Dystrophy Support Group. The funders had no role in the study design, data
collection, analysis, interpretation of data, writing the report, or decisions regarding when to
submit publications.” The authors regret the error.
Reference
1. Cumming SA, Jimenez-Moreno C, Okkersen K, et al. Genetic determinants of disease severity in the myotonic dystrophy type 1
OPTIMISTIC cohort. Neurology 2019;93:e995–e1009.
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